Regulatory delays for biosimilars in U.S.
Denosumab received CRL from FDA due to partner Alvotech's facility issues; Rituximab requires re-inspection. Both face delays of at least 6-12 months.
high · management_commentary
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Lenalidomide revenue cliff from Q4
CEO advised to assume zero lenalidomide revenue from Q4 FY26, which will impact overall revenue and margins.
high · management_commentarySemaglutide pricing pressure and competition
Management expects eventual competition in Canada and other markets, with pricing likely settling at lower end of $20-$70 range.
medium · analyst_questionSG&A cost growth moderation uncertain
SG&A as % of revenue remains elevated at 30% (ex-one-off); management expects growth to moderate but absolute level may not decline.
medium · analyst_question